Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PLAGL2 |
| Gene Name: | PLAGL2 |
| Alias: | Pleiomorphic adenoma-like protein 2 |
| Mass (Da): | 54584 |
| Number AA: | 496 |
| UniProt ID: | Q9UPG8 |
| Locus ID: | 5326 |
| COSMIC ID: | PLAGL2 |
| Gene location on chromosome: | 20q11.21 |
| Cancer protein type: | OP (possibly) |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES (possibly) |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.42 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | PLAGL2 is a transcription factor, but it only displays weak transcriptional activatory activity. It appears, however, that it can bind and activate IGF-II gene promoter and promote the activation of the IGF-II mitogenic pathway. However, it may also interact with HIF-1 and activate apoptosis. Combined evidence suggests that it likely plays a larger oncogenic role versus tumour suppressor role, but its specific functions are not well understood. |